Year All202320222021202020192018 June 1, 2023 Oculis to Participate in Jefferies Healthcare Conference May 31, 2023 Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares May 31, 2023 Oculis Announces Upcoming Presentation of Positive Stage 1 Top Line Results from Phase 3 DIAMOND Trial at Clinical Trials at the Summit (CTS) May 30, 2023 Oculis Announces Launch of Proposed Public Offering of Ordinary Shares May 24, 2023 Oculis to Participate and Present at Upcoming EuDES Meeting May 22, 2023 Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops May 11, 2023 Oculis Co-founders Selected as Finalists in European Inventor Award 2023 April 26, 2023 Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs April 5, 2023 Oculis to Participate at Upcoming Investor Conferences April 4, 2023 Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
May 31, 2023 Oculis Announces Upcoming Presentation of Positive Stage 1 Top Line Results from Phase 3 DIAMOND Trial at Clinical Trials at the Summit (CTS)
May 22, 2023 Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
April 26, 2023 Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
April 4, 2023 Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
